{"id":266950,"date":"2026-09-24T11:35:08","date_gmt":"2026-09-24T06:05:08","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=266950"},"modified":"2026-09-24T11:35:08","modified_gmt":"2026-09-24T06:05:08","slug":"bliss-gvs-pharma-best-stock-in-its-sector","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-best-stock-in-its-sector\/","title":{"rendered":"Is Bliss GVS Pharma the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"

Bliss GVS Pharma CMP Rs 691 (24 Sep 2026). Market cap Rs 7,411 Cr. ROE 10.82%. P\/E 52.28x versus Industry P\/E 38.33x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Bliss GVS Pharma is one of the names investors compare when screening the Healthcare sector, built on a 10.82% return on equity and a P\/E of 52.28x against an Industry P\/E of 38.33x. Whether Bliss GVS Pharma is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.<\/p>\n<\/p><\/div>\n

Is Bliss GVS Pharma<\/a> the best stock in its sector? The stock trades on the NSE at Rs 691 as of 24 September 2026, within its 52-week range of Rs 118.00 to Rs 728.00. Bliss GVS Pharma Ltd manufactures pharmaceutical formulations including suppositories and other specialised dosage forms.<\/p>\n

Bliss GVS Pharma sits in the Healthcare sector, and its 10.82% ROE and 52.28x P\/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P\/E benchmark.<\/p>\n

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n